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Activation of the farnesoid X receptor (FXR) has indicated a
therapeutic potential for this nuclear bile acid receptor in the
prevention of diabetic nephropathy and obesity-induced renal
damage.Here,we investigated the protective role of FXRagainst
kidney damage induced by obesity in mice that had undergone
uninephrectomy, a model resembling the clinical situation of
kidney donation by obese individuals. Mice fed a high-fat diet
developed the core features of metabolic syndrome, with subse-
quent renal lipid accumulation and renal injury, including glo-
merulosclerosis, interstitial fibrosis, and albuminuria. The
effects were accentuated by uninephrectomy. In human renal
biopsies, staining of 4-hydroxynonenal (4-HNE), glucose-regu-
lated protein 78 (Grp78), and C/EBP-homologous protein,
markers of endoplasmic reticulum stress, was more prominent
in the proximal tubules of 15 obese patients compared with 16
non-obese patients. In mice treated with the FXR agonist obe-
ticholic acid, renal injury, renal lipid accumulation, apoptosis,
and changes in lipid peroxidation were attenuated. Moreover,
disturbed mitochondrial function was ameliorated and the
mitochondrial respiratory chain recovered following obetich-
olic acid treatment. Culturing renal proximal tubular cells with
free fatty acid and FXR agonists showed that FXR activation
protected cells from free fatty acid-induced oxidative stress and
endoplasmic reticulum stress, as denoted by a reduction in the
level of reactive oxygen species staining and Grp78 immuno-
staining, respectively. Several genes involved in glutathione
metabolismwere induced by FXR activation in the remnant kid-
ney, which was consistent with a decreased glutathione disul-
fide/glutathione ratio. In summary, FXR activation maintains
endogenous glutathione homeostasis and protects the kidney in
uninephrectomized mice from obesity-induced injury.
Obesity is an independent risk factor for a rapid decline in
renal function in patients with glomerular disease and chronic
kidney disease (1–3). Several pathophysiological mechanisms
underlie the development of renal injury in obesity (4, 5).
Among them, renal lipid accumulation and lipotoxicity report-
edly play important roles in the pathogenesis of renal injury,
although the precise mechanisms have not yet been fully eluci-
dated (6–8).
Lipotoxicity occurs when excess free fatty acid (FFA)2 accu-
mulates in non-adipose tissues or cells, such as hepatocytes,
pancreatic cells, and renal epithelial cells, thereby contributing
to the pathogenesis of obesity, diabetes, and related metabolic
disorders (9–11). FFA at levels exceeding the renal capacity for
oxidation induces reactive oxygen species (ROS), oxidative
stress, and ER stress, all of which play crucial roles inmediating
renal injury (12–14). ROS are highly reactive molecules that
oxidize lipids and proteins, cause cellular injury, and promote
glomerular and renal tubular injury and associated proteinuria
(15, 16). Thus, modulation of ROS can be beneficial in amelio-
rating FFA-induced kidney damage (17, 18).
The farnesoidX receptor (FXR) is a nuclear bile acid receptor
that plays crucial roles in bile acid, cholesterol, lipid, and glu-
cose metabolism in the liver and intestine. In the liver, FXR
activation exerts antifibrotic effects by several mechanisms,
including increased apoptosis of hepatic stellate cells (19). FXR
activation is also associated with antioxidative effects. Mice fed
a high-fat diet (HFD) develop proteinuria and renal lipid accu-
mulation, exhibit increased oxidative stress, and express profi-
brotic growth factors. Treatment of these mice with the selec-
tive and potent FXR agonists obeticholic acid (OCA) and
GW4064 decreased triglyceride accumulation by modulating
fatty acid synthesis and oxidation, reduced renal injury, and
modulated inflammation, oxidative stress, and fibrosis (20–
22). However, the mechanisms by which FXR activation
reduces oxidative stress are not well understood.
The purpose of this study was to investigate the roles of
FXR activation in regulating renal lipid oxidation and in pre-
venting renal injury. We had shown previously that unine-
phrectomy (UNX) augments the effects of HFD-induced obe-
sity on mouse kidney (23). Consequently, we first examined
whether the mechanisms of HFD-induced renal damage, in
particular the mechanisms of lipid peroxidation and subse-
quent oxidative stress, are affected by reduced renal mass. Fur-
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metabolism and protects against renal injury by treating mice
with OCA, an FXR agonist found previously to be protective
against HFD-induced renal injury (21). From a clinical perspec-
tive, the increasing prevalence of obesity among kidney donors
could impose a risk on the integrity of the remaining kidney
(24). The prospect of protecting kidney function in obese kid-
ney donors by pharmacological activation of FXR opens up new
therapeutic options for this expanding patient population.
Experimental Procedures
Animal Procedures—Female C57/BJ mice aged 6 weeks were
randomly assigned to UNX or sham procedures and were fed
with a HFD (D12331, Provimi Kliba, Switzerland) or a chow
diet (D12329, Provimi Kliba). For UNX, mice were initially
anesthetized with 3–5% isoflurane, intubated orally, and venti-
lated mechanically. Anesthesia was maintained with 1.5–2%
isoflurane delivered in oxygen. The left kidney was surgically
removed via a left paramedian incision on the back. The adrenal
gland was carefully freed from the upper pole of the renal cap-
sule before the renal pedicle was ligated and the kidney
removed. For sham surgery, the same procedure was followed,
except that the kidney wasmanipulated without ablation. After
surgery, mice were fed a chow diet for 1 week until recovery,
and then the diet intervention started with a chow diet or HFD.
After 8 weeks of a HFD, half of the obese mice were given OCA
(25 mg/kg mixed into the diet, Intercept Pharmaceuticals) to
activate FXR (22). Finally, mice were divided into six groups of
six animals: sham-chow, UNX-chow, sham-HFD, UNX-HFD,
sham-HFD-OCA, and UNX-HFD-OCA. All mice were killed
under anesthesia 17 weeks after surgery, and their kidneys were
harvested. Half of the kidney from each animal was snap-frozen
in liquid nitrogen and stored at 80 °C for RNA and protein
extraction. The other half was fixed with formalin for histolog-
ical examination.
Measurement of Plasma and Urine Samples—For 24-h urine
collection, individual mice were placed in metabolic cages with
access to diet. Urinary albumin and creatinine concentrations
were measured with the albumin mouse ELISA kit (ab108792,
Abcam, Cambridge, UK) and creatinine assay kit (ab65340,
Abcam). Urinary H2O2 levels weremeasured using the Amplex
Red H2O2 assay kit (A12214, Invitrogen). Plasma samples were
obtained from the tail blood of fasted mice. Plasma choles-
terol and triglyceride levels weremeasured using the Amplex
Red cholesterol assay kit (A12216, Invitrogen) and the trig-
lyceride assay kit (ETGA-200, EnzyChrom, Aachen, Ger-
many), respectively.
Assessment of Renal Pathology and Immunostaining—Kid-
neys were fixed overnight in 10% neutral buffer formalin and
embedded in paraffin. Tissue sections were cut at 3 m and
stained with hematoxylin and eosin, periodic acid-Schiff (PAS),
and Masson’s trichrome stain using standard protocols. The
mesangial area was determined from the PAS-stained sections,
and the fibrotic area was assessed from the trichrome stained
sections. Briefly, digital images of random high-power fields
were analyzed by a blind observer. The cross-sectional areas of
the glomeruli and the area of fibrosis were determined using
Adobe Photoshop. Sixmicewere analyzed per group. Immuno-
stainingwas performedonparaffin sections using amicrowave-
based antigen retrieval technique. The antibodies used in this
study included Grp78 (ab21685, Abcam), CHOP (ab59396,
Abcam), LC3b (ab48394, Abcam), 4-HNE (ab46545, Abcam),
Cyp4a (sc-98988) and succinate dehydrogenase, subunit A
(SDHA, catalog No. 11998, Cell Signaling Technology). Sec-
tions were treated with the EnVision diaminobenzidine kit
(DAB, Dako, Glostrup, Denmark) according to the manufactu-
rer’s instruction. TUNEL staining on kidney paraffin sections
was performed according tomanufacturer’s instructions (Apo-
pTag, Millipore, Billerica, MA). Quantitative analyses of sec-
tions immunostained for 4-HNE, SDHA, and LC3b were done
as described previously (25).
Isolation of Primary Proximal Tubule Cells—Primary proxi-
mal tubule cells were isolated from kidneys of C57/BJ mice as
described previously (25). Briefly, kidney cortices were dis-
sected, sliced, minced, and digested in 0.25% trypsin solution
(Life Technologies BRL) in a shaking incubator at 37 °C for 1 h.
Trypsinwas neutralizedwith growthmedium (DMEMand10%
FBS containing 100 units/ml penicillin and 0.1 mg/ml strepto-
mycin). The suspension was pipetted and then passed through
a 100-mcell strainer (BDBiosciences). The sampleswere cen-
trifuged (72.4 g for 5 min) to pellet the tubules, washed with
10 ml of medium, centrifuged, and washed twice more. The
final pellet, consistingmostly of renal tubules, was resuspended
in culture medium (renal epithelial basal medium (REBM),
BulletKit, Clonetics), plated onto culture dishes (Nalge Nunc
International, Naperville, IL), and incubated at 37 °C in a car-
bon dioxide incubator with medium changed every 2 days until
the cells were confluent. Experiments were carried out in
serum-free DMEM. After 12 h under starvation conditions in
0.2% FBS/DMEM, cells were incubated by the addition of 100
M chenodeoxycholic acid (Sigma-Aldrich), 1 M GW4064
(Sigma-Aldrich), or 1 M OCA overnight. Of the several types
of FFAs, only palmitate acid reportedly showed cytotoxic
effects in cultured proximal tubular cells (26, 27). Conse-
quently, we assessed the effects of palmitate acid-boundBSAon
oxidative stress and ER stress in primary cultured cells. Cells
were starved by incubation in 0.2% FBS/DMEM for 12 h fol-
lowed by overnight stimulation with 150 M palmitate acid
bound to 8% BSA. Where indicated, cells were pretreated with
OCA (1 M) 1 h before treatment with palmitate acid. Lipid-
containing medium was prepared by the conjugation of FFA
with FFA-free BSA. Briefly, sodium palmitate was dissolved in
50% ethanol and mixed vigorously with FFA-free BSA in PBS.
FFA-free BSA was used as the control.
Cell Staining—After treatment, cells were washed with cold
PBS, fixed in 4% paraformaldehyde, and treated with 0.1%
Triton X-100 in PBS for 15 min and with 0.1% Tween 20 in
1% BSA/PBS for 30 min. Then, the cells were incubated with
primary antibody at 4 °C overnight. The cells were washed
and incubated with secondary antibody for 1 h in the dark.
After being washed, the cells were stained with ActinRed
(R37112, LifeTechnologies) orActinGreen (R37110, LifeTech-
nologies) probes at room temperature for 30 min and then
washed three times. Next, the cells were mounted with DAPI
(Vector Laboratories) and visualized under a fluorescent
microscope (Leica DMI6000B). Antibodies against Grp78 were
purchased from Abcam. For intracellular ROS detection (Cell-
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ROX deep red, Life Technologies), glutathione detection
(ThiolTracker Violet, T10095, Life Technologies), and TUNEL
staining (ApopTag, Millipore), cells were processed according
to the manufacturer’s methods.
Lipid Staining—To examine the accumulation of lipids, fro-
zen kidney sections and primary cultured proximal tubular
cells were stained with BODIPY 493/503 (D-3922, Invitro-
gen). Briefly, for frozen kidney, slides were washed twice
with PBS, and for cells, chamber slides with proximal tubule
cells were fixed in 4% paraformaldehyde and washed twice
with PBS. Slides were then incubated with 1 g/ml BODIPY
493/503 in 150mMNaCl for 20min at room temperature. After
incubation, slides were washed twice with PBS, mounted with
DAPI, and visualized under a fluorescent microscope (Leica
DMI6000B).
Mitochondrial ToxGlo Assay—The mitochondrial Tox-
GloTM assay was performed according to the manufacturer’s
protocol (Promega). The assay is based on the sequential mea-
surement of biomarkers associated with changes in cell mem-
brane integrity and cellular ATP levels. Briefly, cells were
seeded at 200,000 cells/ml in 96-well plates with serum-free
medium. Cells were treated with 150 M palmitate acid treat-
ment with or without OCA (1 M) for up to 16 h. First, cell
membrane integrity was assessed by measuring fluorescence
(485 nmex/520–530 nmem) after a 30-min incubation with a
bis-AAF-R110 peptide substrate designed to monitor the pres-
ence or absence of a distinct protease activity associated with
necrosis. The bis-AAF-R110 peptide substrate is impermeable
for intact cell membranes, and no signal is detected with viable
cells. Protease activity can be detected only when cells have a
compromised membrane. Next, cellular ATP was measured by
adding an ATP detection reagent resulting in cell lysis and gen-
eration of a luminescent signal proportional to the amount of
ATPpresent. TheATPdetection reagent contains luciferin and
Ultra-GloTM luciferase and when added to cells reports on the
ATP content. ATP is the limiting reagent in the assay.
Isolation of Kidney andCell RNAandQuantification of Tran-
script Levels—Total RNA was prepared using Trizol (Invitro-
gen). The amount of mRNA was determined from the absor-
bance at 260 nm. After DNase treatment (Promega), 2 g of
total RNAwas reverse-transcribed using oligo(dT) priming and
Superscript II (Invitrogen). First-strand complementary DNA
was used as the template for real-time polymerase chain reac-
tion analysis with TaqMan master mix and primers (Applied
Biosystems). Transcript levels, determined in two independent
complementary DNA preparations, were calculated and
expressed relative to villin as the housekeeping gene.
Microarray and Gene Expression Analysis—RNA was ex-
tracted from primary cultured mouse proximal tubule cells
using an RNeasy microarray tissue mini kit (73304, Qiagen)
followed by on-column DNase digestion to remove any con-
taminating genomic DNA. RNA samples from four dishes/
group were subjected to microarray analysis. Briefly, 100 ng of
total RNA was reverse-transcribed into double-stranded
cDNA, which was linearly amplified and labeled with Cy3 dye.
Following quantification using a NanoDrop spectrophotome-
ter (Witec, Luzern, Switzerland) and quality assessmentwith an
Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara,
CA), 1.6 g of the obtained Cy3-labeled cRNA was hybridized
to mouse GE 444K v2 microarrays (Agilent) according to the
manufacturer’s protocol. Arrays were scanned with an Agilent
G2565CA microarray scanner system (Agilent raw intensity
data were obtained using Agilent’s Feature Extraction software,
version 10.7, for array image analysis and the calculation of spot
intensities). Data analysis was carried outwith R/Bioconductor.
The processed intensities were normalized across samples and
loaded by using quantile normalization. All microarray data
were submitted to the Gene Expression Omnibus (accession
number GSE70296). Differential expression was computed
using the Limma package. Gene ontology analysis, network
analysis, and Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway analysis of the microarray data were com-
pleted using the MetaCore online service (Thomson Reuters)
and DAVID Bioinformatics Resources (NIAID, National Insti-
tutes of Health).
Western Blotting—Lysates (20g of protein) from kidney tis-
sue or cells were separated by SDS-PAGE and blotted on poly-
vinylidene difluoride membranes (Millipore). The membranes
were blocked with TBS containing 0.1% Tween 20 and 3% BSA
for 1 h at room temperature and incubated overnight at 4 °C
with the respective antibodies. Subsequently, the blots were
washed with TBS containing 0.1% Tween 20, treated with
horseradish peroxidase-conjugated secondary antibodies at
room temperature for 1 h, and developed using the ECL Plus
detection system (Amersham Biosciences). The antibody
against villin was from Chemicon (MAB1639a); anti-Osta (sc-
100078) and anti-Shp (sc-30169) were from Santa Cruz Bio-
technology (Dallas, TX), anti-caspase 3 (catalogNo. 9661) from
Cell Signaling (Danvers, MA), and anti-p62 (ab91526) from
Abcam.
Patients—Kidney sampleswere provided byDr. LeiChu from
the Minimally Invasive Urology Center, Provincial Hospital
affiliated to Shandong University. Thirty-one patients with
minimal change disease (MCD), as diagnosed by ultrasonogra-
phy-guided percutaneous biopsy of the kidney, in whom overt
proteinuria was above 1.0 g/day, were included. The exclusion
criteria were: (a) body mass index  40 kg/m2; (b) history of
type 2 diabetes mellitus; (c) renal, cardiovascular (heart failure,
previous myocardial infarction), liver, or thyroid diseases; and
(d) use of drugs known to affect the parameters under investi-
gation. Participants had stable body weight (weight change 5
kg during the last 6 months). Demographic data on both
groups, such as gender, age, weight, and height are given in
Table 2.
Statistics—Data are expressed asmean S.E. Formicroarray
data, a comparison was assessed by Student’s t test with R/Bio-
conductor to generate differentially expressed genes (control
versus GW4064). For other data relating to baseline character-
istic analysis and histological analysis, comparisons between
groups were assessed by one-way ANOVA followed by Bonfer-
roni’s test. Statistical analyses were performed using GraphPad
software.
Study Approval—All animal experiments and protocols con-
formed to the Swiss animal protection laws and were approved
by theCantonal VeterinaryOffice in Zurich, Switzerland (study
number 2012058). The human study was conducted according
FXR and Kidney Injury
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to theDeclaration ofHelsinki guidelines regarding ethical prin-
ciples for medical research involving human subjects. All
patients provided written informed consent, and the study pro-
tocol was approved by the Scientific Ethical Committee of
Shandong University, Jinan, China, where patients were based
(license number SDU2015033).
Results
Chronic FXR Activation by OCA Prevents Hyperlipidemia
and Steatosis and Improves Renal Function—Because UNX
augments the effects of obesity on renal gene expression (23),
we investigated the effects of aHFD in both sham-operated and
UNX mice. The FXR agonist OCA was added to the HFD to
activate FXR. Six groups of mice (n  6) were investigated:
sham-chow, UNX-chow, sham-HFD, UNX-HFD, sham-HFD-
OCA, andUNX-HFD-OCA.OCA treatment was initiated after
8 weeks of HFD and was continued for another 8 weeks. As
shown in Table 1, HFD intervention in both sham and UNX
mice resulted in increased body weight and hyperlipidemia.
Changes in plasma triglyceride and FFA were attenuated in
both sham and UNX obese mice treated with OCA. However,
OCA treatment for 8 weeks in obese mice did not significantly
reduce their body weight (Table 1).
Because OCA treatment decreased plasma triglyceride and
FFA levels in obese mice, the effect on liver steatosis was stud-
ied. HFD induced hepatic steatosis in obese mice as expected
(Fig. 1, B and E), but steatosis was decreased by OCA treatment
(Fig. 1, C and F). We also investigated whether FXR activation
affected obesity-induced progressive kidney dysfunction. HFD
induced a significant elevation of albuminuria and urinary
H2O2 excretion, but these markers were decreased by	50% in
OCA-treated mice (Fig. 2).
FXR Activation by OCA Reduces Glomerulosclerosis and
Tubulointerstitial Injury in Obese Mice—Both sham-HFD and
UNX-HFD mice developed significant increases in PAS-posi-
tive hypertrophy of glomeruli,mesangialmatrix, and tubuloint-
erstitial fibrosis at week 16 (Fig. 3, A and C). UNX-HFD mice
had the highest levels of glomerulosclerosis and interstitial
fibrosis (Fig. 3, Ae, and Ce). Obese mice from both sham and
UNX groups treated withOCA showed notable improvements,
with reduced tubulointerstitial fibrosis and less mesangial
matrix (Fig. 3, A, c and f, and C, c and f). Quantitative analyses
with scores for glomerulosclerosis and interstitial fibrosis indi-
cated that the reduction in glomerular damage and tubuloint-
erstitial fibrosis was significant in both the sham-HFD-OCA
and UNX-HFD-OCA groups compared with the HFD groups
(Fig. 3, B and D).
Improved Renal Function Is Associated with Reduced Lipid
Accumulation and Reduced ROS—We next analyzed lipid
accumulation and oxidation in the kidney because these are
considered major causes of obesity-induced renal damage (28).
BODIPY 493/593 was used to stain neutral lipids. Both sham-
operated and UNX obese mice possessed significantly
increased numbers of lipid droplets in kidney compared with
chow-fed mice (Fig. 4A, b and e). UNX-HFD mice had higher
levels of positive lipid staining than sham-HFD mice. OCA
treatment decreased lipid accumulation in the kidney (Fig. 4,A,
FIGURE 1. FXR activation ameliorates the development of liver steatosis. A–F, representative H&E staining of liver sections from sham-chow (A and D),
sham-HFD (B and E), and sham-HFD-OCAmice (C and F). D–F, higher magnification of selected boxed areas from images A–C, respectively. n 6/group.
TABLE 1
Characteristics of the mice in the six groups after treatment
TG, triglyceride; Cho, cholesterol. n 6 mice/group; data are expressed as the mean S.E., one-way ANOVA with Bonferroni’s test.
Sham UNX
Sham-Chow Sham-HFD Sham-HFD-OCA UNX-Chow UNX-HFD UNX-HFD-OCA
Body weight (g) 22.00 0.58 28.80 2.13a 27.67 1.50a 21.33 0.42 31.00 2.12a 27.50 1.29a
Kidney weight (mg) 140.0 6.8 143.3 4.2 143.3 8.0 191.7 9.5 201.7 12.7 186.7 10.5
Plasma TG (mg/dl) 131.7 2.2 146.4 3.6a 129.1 3.9b 140.5 2.9 153.5 3.2a 133.2 4.3b
Plasma Cho (mg/dl) 62.9 5.3 79.3 4.0a 77.5 1.5a 66.3 4.6 83.1 4.2a 76.5 4.3
Plasma FFA (mmol/liter) 1.095 0.084 1.422 0.165a 0.667 0.059b 1.004 0.047 1.415 0.126a 0.667 0.052b
a p 0.05, comparison between chow diet and HFD.
b p 0.05, comparison between HFD and HFD-OCA.
FXR and Kidney Injury
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c and f, and B), consistent with decreased plasma triglyceride
and FFA levels (Table 1). Thus, the reduction in kidney injury
and lipid accumulation observed in OCA-treated mice (Figs.
3 and 4A)matched the improvement in kidney function (Fig. 2),
indicating a correlation between improved renal function and
reduced lipid accumulation. Although the initial events
involved in lipid-mediated renal damage are unclear, lipid oxi-
dation and subsequent oxidative stress play an important role
(11). Mice fed a HFD showed increased levels of 4-HNE (Fig.
4C, b and e), an aldehydic product of lipid peroxidation and a
biomarker for oxidative stress. UNX-HFD mice showed the
highest level of oxidative stress (Fig. 4Ce), and the degree of
FIGURE 2. Albuminuria and urinary H2O2 output in the six treatment groups. A, the urine albumin/creatinine (Al/Cr) ratio increased at 16 weeks in both
sham-HFD andUNX-HFDmice, and this increasewas attenuated byOCA treatment. n 6mice/group. B, the urineH2O2/creatinine ratio increased at 16weeks
in both sham-HFDandUNX-HFDmice, and this increasewas attenuatedbyOCA treatment.n 6mice/group.Data are shownasmean S.E. One-wayANOVA
with Bonferroni’s test. *, p 0.05.
FIGURE 3. Effects of FXR activation on glomerular and tubulointerstitial injury. Representative images ofMasson’s trichrome-stained (A) and PAS-stained
(C) sections of kidney tissue from the six treatment groups. n 6mice/group. B andD, bars represent the quantitative analysis of the area of fibrosis (B) and the
mesangial area (D). n 6 mice/group. Data are expressed as mean S.E. One-way ANOVA with Bonferroni’s test. *, p 0.05.
FXR and Kidney Injury
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positive staining for 4-HNEwas reduced in OCA-treated obese
mice (Fig. 4C, c and f). Quantitative analysis of positive 4-HNE
staining confirmed a 4-fold increase in 4-HNE staining in
UNX-HFD compared with sham-chow mice, which was re-
duced	50% by OCA treatment.
Because FXR activation by OCA almost completely resolved
obesity-induced kidney damage, we examined whether FXR
activation affected expression of genes involved in fatty acid
synthesis and oxidation. In line with previous studies (21, 29),
HFD showed a tendency to increase expression of Srebf1c and
Srebf2, which regulate fatty acid synthesis and cholesterol syn-
thesis separately. However, activation of FXR did not result in
significant changes in either Srebf1c or Srebf2 (Fig. 4E), indicat-
ing that decreased renal lipid content in OCA-treatedmice was
not caused by modulation of fatty acid synthesis. However, we
found that FXR activation increased renal expression of acyl-
CoA oxidase 1 (Acox1), carnitine palmitoyltransferase 1a
(Cpt1a), peroxisome proliferator-activated receptor  (Ppara),
and cytochrome P450 4a14 (Cyp4a14) mRNAs (Fig. 4E), all of
which are important for fatty acid oxidation and lipid catabo-
lism. These findings were consistent with previous studies (21,
27). Cyp4a14 is a downstream gene regulated by PPAR, and
Cyp4a14 is a key enzyme involved in FFA-oxidation in the ER.
Fig. 4D illustrates representative immunostaining of Cyp4a14
in kidney tissues from different groups. Cyp4a14 levels in prox-
imal tubular epithelial cells were low in the chow-fed group.
FIGURE 4. Effects of FXR activation on lipid accumulation and oxidation in kidneys of mice from the six treatment groups. A, representative images of
BODIPY staining on renal sections from the different treatment groups. n 6mice/group. B, quantitative analysis of the number of lipid droplets and positive
staining of 4-HNE per high power field. n  6 mice/group. Data are expressed as mean  S.E. One-way ANOVA with Bonferroni’s test. *, p  0.05. C and D,
representative images of immunostaining for 4-HNE (C) and Cyp4a (D). n 6mice/group. E, quantification of mRNA levels of genes associated with fatty acid
synthesis (Srebf1c and Srebf2), -oxidation (Acox1 and Cpt1), and -oxidation (Ppara and Cyp4a14). n 4–6 mice/group. Data are expressed as mean S.E.
One-way ANOVA with Bonferroni’s test. *, p 0.05.
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Expression in mice fed a HFD was greatly increased, and OCA
treatment further induced the expression of Cyp4a14 (Fig. 4D,
c and f), consistent with the observed increase in mRNA levels.
Thus, treatmentwithOCA stimulates renal fatty acid oxidation
and renal lipolysis, thereby resulting in reduced kidney lipid
accumulation in obese mice.
Lipid oxidation, especially fatty acid oxidation, occursmostly
in mitochondria. To evaluate renal mitochondrial function, we
measured the expression of succinate dehydrogenase, a key
enzyme involved in themitochondrial respiratory chain, in kid-
ney sections (Fig. 5A). By immunostaining for SDHA, both
sham and UNX mice fed a HFD showed decreased levels of
renal SDHA staining (Fig. 5A, b and e). However, SDHAexpres-
sion was partially recovered in OCA-treated mice on a HFD
(Fig. 5, A, c and f, and C), indicating that FXR activation
improved mitochondrial function and induced the mitochon-
drial respiratory chain. Autophagosomes and autophagic flux
normally regulate the mitochondrial life cycle, whereas dis-
turbed autophagosome formation impedes the removal of
damagedmitochondria, resulting inmitochondrial dysfunction
(30). Immunostaining of mouse kidney sections for Lc-3b, a
marker for autophagy (Fig. 5B), showed that autophagosomes
were localized mainly on the glomerular basement, where the
podocytes reside (Fig. 5B, a, inset). Lower levels of Lc-3b stain-
ing were found as obesity-induced nephropathy progressed
(Fig. 5B, b and e), confirming previous findings (31, 32). How-
ever, FXR activation attenuated the decrease in the number of
autophagosomes in both sham-operated and UNX obese mice
(Fig. 5, B, c and f, and D). Immunoblotting results for p62,
another autophagosome marker, confirmed that OCA treat-
ment attenuated the decrease of autophagosomes in obesemice
(Fig. 6D). This finding indicates that FXR activation promotes
intracellular organelle recovery mechanisms and probably
helps to maintain the mitochondrial life cycle, consistent with
the SDHA staining shown in Fig. 5A. Thus, FXR activation
maintains effective mitochondrial FFA oxidation in kidney tis-
sue of obese mice.
FXR Activation by OCA Contributes to Lower Levels of ER
Stress and Reduced Apoptosis—Because obesity has been
shown to cause ER stress in liver and adipose tissue (33),
we studied the expression of ER stress proteins in kidney
tissue. Staining for the ER markers Grp78 and CHOP (Fig. 6,
A and B) showed higher ER stress in both obese sham-oper-
ated and UNX mice. In contrast, limited ER stress was
FIGURE 5. Effects of FXR activation on themitochondrial respiratory chain and themitochondrial life cycle in kidneys ofmice from the six treatment
groups.A and B, representative images of immunostaining for SDHA (A), amarker of themitochondrial respiratory chain, and Lc-3b (B), amarker of autophagy,
on renal sections ofmice from the six treatment groups. n 6mice/group. C andD, quantitative analysis of the positive staining of SDHA (C) and LC3b (D) per
high power field. n 6 mice/group.
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observed in the OCA-treated groups (Fig. 6, A, c and f, and B,
c and f), indicating that FXR activation ameliorated HFD-
induced ER stress. The increased expression of Grp78 at the
protein level in UNX-HFD mice was also confirmed by
immunoblotting (Fig. 6D).
To translate these findings into the clinical situation,wemea-
sured markers of lipid peroxidation and ER stress in renal
biopsy specimens from 16 non-obese and 15 obese human
subjects with minimal change disease (overt proteinuria 1
g/day) in the kidney (patient data are shown in Table 2). The
proximal tubules from non-obese patients showed little pos-
itive staining for 4-HNE, GRP78, or CHOP, whereas all three
stained more prominently in kidney biopsies from obese
patients (representative examples are shown in Fig. 7, B, D,
and F). These findings support the concept that ER stress in
kidney is important in the progression of obesity-induced
kidney damage in human.
FIGURE 6. Effects of FXR activation on the markers of ER stress in kidneys of mice from the six treatment groups. A–C, representative images of
immunostaining for Grp78 (A) and CHOP (B) and of TUNEL staining (C). Arrows indicate apoptotic bodies. n 6mice/group.D, Western blot analysis of Grp78,
caspase-3, and p62 protein levels in kidney samples of sham-chow, UNX-HFD, and UNX-HFD-OCAmice.
TABLE 2
Demographic information on patients with minimal change kidney
disease
BMI, body mass index. Values represent mean S.E., Student’s t test, *, p 0.05.
Groups BMI< 25a 25< BMI< 40b p values
Sex (male/female) 6/10 6/9 0.315
Age (year) 55.42 2.641 52.25 2.843 0.420
Weight (kg) 65.53 1.667 80.87 2.667 *0.001
Height (cm) 171.3 2.275 168.9 1.438 0.341
BMI (kg/m2) 22.88 0.40 29.04 0.77 *0.001
a n 16.
b n 15.
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Apoptosis is a common sequel of chronic ER stress, and
accordingly, TUNEL staining showed increased apoptosis in
the kidneys of obese mice, with the highest level in UNX-HFD
mice (Fig. 6C, b and e). FXR attenuatedHFD-induced apoptosis
in obese mice. The levels of caspase-3 were increased in the
kidney of UNX-HFDmice and decreased in OCA-treated mice
as shown in in immunoblots (Fig. 6D). Taken together, the evi-
dence indicates that FXR activation improved ER dynamics and
protected kidney proximal tubular cells fromER stress-induced
apoptosis.
FXR Activation Protects Kidney Proximal Tubular Cells by
Inducing GlutathioneMetabolism—To better assess the role of
FXR in reducing oxidative stress and ER stress, we cultured
primary proximal tubular cells frommouse kidney and exposed
the cells to FFA and/or FXR agonists. OCA treatment success-
fully activated FXR, as demonstrated by increased expression of
Shp, Osta, and Ostb (Fig. 8, A and B), all of which are down-
stream genes directly regulated by FXR. Similar results were
also obtained from proximal tubular cells treated with cheno-
deoxycholic acid and GW4064, other known FXR agonists, as
positive controls (data not shown). As shown in Fig. 8D, expo-
sure of cells to FFA resulted in lipid accumulation, oxidative
stress, and ER stress as denoted by significantly higher levels of
BODIPY staining, ROS staining, and Grp78 immunostaining,
respectively (Fig. 8D, b, e, and h). Grp78 protein levels were also
increased in immunoblots (Fig. 8C). It is noteworthy that the
activation of FXR in proximal tubular cells resulted in signifi-
cantly reduced lipid accumulation, oxidative stress, and ER
stress in response to FFA (Fig. 8D, c, f, and i). Moreover, apo-
ptosis was blocked when cells were incubated with FFA and
exposed to OCA, as indicated by TUNEL staining (Fig. 8Di),
consistent with membrane integrity analysis (Fig. 8F).
The expression of genes involved in FFA synthesis and oxi-
dationwas also investigated in primary cultured proximal tubu-
lar cells exposed to FFA (Fig. 8E). FXR activation byGW4064 or
OCA increased expression of Ppara,Cpt1a, andCyp4a14, con-
sistent with the mRNA levels in kidney tissue of OCA-treated
HFD mice (Fig. 4E). Furthermore, mitochondrial function was
assessed by mitochondrial ATP generation (Fig. 8F). After a
16-h treatment with FFA, cells showed a decreased ATP con-
tent as ameasure ofmitochondrial function in these cells. How-
ever, cells co-treated with OCA and FFA showed a significant
increase ofATP levels comparedwith the FFA treatment group.
Taken together, these results indicate that FXR activation pro-
tects renal proximal tubular cells by reducing oxidative stress
and ER stress, improvingmitochondrial function, and stimulat-
ing fatty acid oxidation.
The apparently opposing effects of FXR in inducing fatty acid
oxidation while at the same time reducing oxidative stress were
further investigated by microarray analysis of renal proximal
tubular cells exposed either to GW4064 or dimethyl sulfoxide
(as a control). By using a 1.7-fold change as the cut-off point,
expression of 357 geneswas significantly increased by FXR acti-
vation, and expression of 193 genes was significantly decreased
(Fig. 9A and supplemental Table S1). Interestingly, a KEGG
pathway analysis indicated that several pathways linked to fatty
acidmetabolism and oxidation reduction were induced by FXR
activation (Fig. 9B and Table 3). Among these pathways, genes
involved in glutathione metabolism were induced most prom-
inently (Fig. 9B). Furthermore, by comparing publicly available
chromatin immunoprecipitation-deep sequencing (ChIP-seq)
data (34) with our microarray data, we found that many of the
genes induced in mouse liver in vivo were also induced in
mouse proximal tubular cells (e.g. genes involved in glutathione
metabolism, fatty acid degradation, and oxidation reduction),
indicating a universal role of FXR in reducing oxidative stress (a
list of the common genes in both data sets is given in Table 4).
To confirm this finding, we investigated glutathione metabo-
lism and the expression of glutathione-metabolizing genes in
proximal tubular cells treatedwith FXR agonists. Co-treatment
of cells with FFA and FXR agonists resulted in significantly
increased intracellular glutathione levels; induced mRNA
expression ofGclm,Gpx1, andGsr; and a decreased glutathione
disulfide/glutathione (GSSG/GSH) ratio (Fig. 10, A and B).
Consequently, the mechanism by which FXR activation pro-
tects cells from ROS appears to be mediated by enhanced glu-
tathionemetabolism andmaintenance of the GSSG/GSH ratio.
Moreover, the expression levels of Gclm and Gsr in the kidney
cortex of OCA-treated obese mice were also increased (Fig.
10C). Consistent with these results, we also found a decreased
GSSG/GSH ratio in the kidney ofOCA-treated obesemice (Fig.
10C).
Discussion
The present study shows that FXR activation in the proximal
tubules of obese mice protects the kidney from FFA-induced
renal damage, consistent with previous data showing that FXR
FIGURE 7. Markers of lipid peroxidation and ER stress in renal biopsy
specimens from non-obese and obese human subjects with minimal
change disease of the kidney. Shown are representative images of immu-
nostaining for 4-HNE (A and B), GRP78 (C andD), and CHOP (E and F) in kidney
specimens obtained fromnon-obese (bodymass index 21 kg/m2 (A, C, and
E) and obese (body mass index  25kg/m2 (B, D, and F) patients with overt
proteinuria (1.0 g/day).
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FIGURE 8. Effect of FXR activation on lipid accumulation, fatty acid oxidation, and oxidative stress in primary cultured proximal tubular cells
(PTCs) exposed to palmitate acid (PA). A and B, representative Western blot images (A) and mRNA analysis (B) of FXR downstream genes in PTCs after
OCA treatment demonstrate that OCA successfully activates FXR in PTCs. n 4/group. Data are presented as mean S.E. *, p 0.05 (Student’s t test)
compared with control group. C, representative Western blot images of Grp78 in cell lysates from PTCs treated with vehicle (FFA-free BSA) and at 24 h
after exposure to palmitate acid (150M)with or without OCA (1M) treatment. n 4/group.D, representative staining of PTCs fromdifferent treatment
groups for lipid droplets (BODIPY staining in a–c), ROS (CellROX staining in d–f), Grp78 (g–i), and apoptosis (TUNEL staining in j, l, and m). Color of
staining corresponds to the label on the left side of each panel. Cells were counterstained with DAPI (blue) and/or ActinRed (red). n  4/group. E,
quantification of mRNA levels of genes associated with fatty acid synthesis (Fasn and Srebf2) and oxidation (Acox1, Cpt1, Ppara, and Cyp4a14) from
different treatment groups. Cont, control; GW, GW4064. n 4/group. Data are expressed as the mean S.E. One-way ANOVA with Bonferroni’s test. *,
p 0.05. F, quantitative analysis of membrane integrity (cytotoxicity) and ATP content from PTCs treated with vehicle (FFA-free BSA) and at 24 h after
exposure to palmitate acid (150 M) with or without OCA (1 M) treatment. n  4/group.
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activation protects renal proximal tubules against obesity-in-
duced kidney damage and diabetic nephropathy (21, 23, 35). In
the context of uninephrectomy, which accentuates the untow-
ard effects of obesity on kidney function, the beneficial effects of
the FXR agonist OCA are novel. Sham-operated obese mice
developed modest renal injury, characterized by reduced renal
function,mesangial expansion, tubular injury, interstitial fibro-
sis, oxidative stress, and ER stress. UNX-HFDmice had a higher
degree of renal injury despite similar body weights. Both sham-
operated and UNX obese mice treated with OCA were largely
protected from renal disease andhad preserved kidney function
with a lower degree of albuminuria and fewer histological
changes comparedwith obesemice not treated withOCA. FXR
activation also inhibited lipid accumulation and FFA-induced
apoptosis in the kidney. Furthermore, FXR activation sup-
pressed FFA-induced oxidative stress by accelerating antioxi-
dant glutathione metabolism and promoting FFA oxidation in
tubular epithelial cells. Consistent with these mouse data, the
immunostaining of human renal biopsy samples also showed
higher levels of lipid peroxidation, oxidative stress, and ER
stress in obese patients. Thus, FXR activation could represent a
novel protective strategy against obesity-induced kidney dis-
ease, notably in the context of uninephrectomy.
In recent decades, the progression of obesity-induced kidney
damage to chronic kidney disease has been a critical focus of
research in nephrology. Several reports have suggested that
renal lipid accumulation and lipotoxicity are associated with
the development of renal injury (6, 7, 36). We and others have
previously reported that feeding a HFD to mice induces renal
lipid accumulation and kidney injury (23, 28, 37). In the present
study, we found increased renal ROS levels and increased oxi-
dative stress in the kidneys of obese mice. ROS are induced in
obesity as a consequence of fatty acid oxidation, and higher FFA
exposure increases fatty acid oxidation and ROS generation,
placing a burden on mitochondria and the ER, where fatty acid
oxidation takes place (38). Failure to remove excessive ROS
results in defective FFA oxidation, oxidative stress, and ER
stress, as shown schematically in Fig. 11A. FXR activation can
protect the kidney by reducing ROS levels and alleviating sub-
sequent oxidative stress and ER stress. FXR activation acceler-
ates glutathione metabolism, which in turn removes excessive
ROS and promotes fatty acid oxidation, providing a plausible
mechanism of action (Fig. 11B).
In this study, altered lipid metabolism was associated with
defective mitochondrial function and fatty acid oxidation. In
the kidney of obese mice, the levels of Acox1 and Cpt1a, mark-
ers of fatty acid oxidation,were not altered, in linewith previous
studies (39). However, FXR activation induced Acox1 and
Cpt1a expression in obese mice. Moreover, FXR activation
induced mitochondrial function (as shown in Fig. 5A by SDHA
staining, a marker of the mitochondrial respiratory chain) and
promoted the mitochondrial life cycle (Fig. 5B, as shown by
induction of the mitochondrial autophagymarker Lc-3b), indi-
cating that defective fatty acid -oxidation occurred in the
mitochondria of obesemice. Recent studies in a diabeticmouse
model and in human patients found defective fatty acid oxida-
tion in renal tubular cells (40–43), consistent with our results.
In contrast, we found increased levels of Cyp4a14, the enzyme
responsible for fatty acid -oxidation in the ER, and a marked
increase of ER stress in the proximal tubules of obesemice. This
increased FFA -oxidation in the ER may explain the signifi-
cant increase ofH2O2 levels detected in the urine of obesemice.
Being themost important organelle involved in protein synthe-
sis, folding, and maturation, the ER takes over fatty acid -ox-
idation when -oxidation is defective in mitochondria (44, 45).
High glucose and FFA levels have been shown to induce ER
stress in podocytes as well as in proximal tubule cells and to
subsequently induce apoptosis (46, 47). Indeed, ER stress can
induce autophagy participating in the degradation of unfolded
proteins and in the repair of damagedmitochondria (48). Expo-
sure to continuous higher levels of energy and nutrients may
activate signals inhibiting autophagic and ER stress responses.
Failure to complete autophagy creates a vicious cycle, resulting
in apoptosis. Consequently, we believe that the ER plays a vital
role in regulating proximal tubular function. However, studies
on the effect of ER stress on kidney function in kidney disease
are limited, and several aspects concerning the signaling path-
FIGURE 9. Effect of FXR activation on gene expression profile in proximal
tubular cells. A, summary of genes differentially expressed in proximal tubu-
lar cells treated with GW4064 for 24 h compared with vehicle control
(dimethyl sulfoxide).n 4/group. The cutoff pointwas a 1.7-fold change, p
0.05. Of the 550 genes significantly differentially expressed after GW4064
treatment, theexpressionof357genes increased (orangebar), and thatof 193
genes decreased (green bar). B, KEGG pathway analysis of genes with an
increase in expression of 1.7-fold. Bold words indicate gene pathways
involved in the reduction of oxidative stress.
TABLE 3
Selected differentially expressed genes in GW4064-treated versus
untreated proximal tubular cells grouped according to function
Numbers in parentheses indicate gene expression levels quantified as Log2 of fold
changes.
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ways that link fatty acid oxidation to ER stress are still
unresolved.
There is growing evidence for the role of dysregulated lipid
metabolism in the pathogenesis of renal disease. A hypernutri-
ent state, as in a HFD model, causes a higher level of lipid oxi-
dation, thereby suppressing intracellular nutrient-sensing sig-
nals (39, 43) and stress resistance mechanisms (49, 50).
Although FXR has been shown to exert a hepatoprotective
effect against various hepatic stress conditions (51), few studies
have assessed FXR activation in obesity-induced kidney dam-
age. FXR activation has been reported to correct metabolic
derangement and improve glucose tolerance and insulin sensi-
tivity, all of which can protect the kidney from diabetic
nephropathy (21, 35). In our study, OCA-treated obese mice
showed modest attenuation of HFD-induced hyperlipidemia
and lipid accumulation. These changes may be explained par-
tially by improved FFA metabolism, with chronic FXR activa-
tion inducing significant expression of genes involved in fatty
acid -oxidation (Acox1 and Cpt1a) and -oxidation (Ppara
andCyp4a14). Previous data have shown that diabetic FXR KO
mice fed a regular chow diet exhibit increased proteinuria,
mesangial expansion, and fibrosis (35), suggesting that FXR is
important inmaintaining kidney function. By exposing primary
cultured mouse kidney proximal tubular cells to FFA and/or
FXR agonists (GW4064 and OCA), we found that FXR activa-
tion reduces ROS and subsequent oxidative stress and ER
stress. This inhibitory effect of FXR on ROS was further inves-
tigated by microarray analysis, which showed that several key
pathways involved in oxidation reduction were significantly
induced by FXR activation, including genes associatedwith glu-
tathione metabolism, arachidonic acid metabolism, fatty acid
degradation, and biosynthesis of unsaturated fatty acids (Fig. 9).
Furthermore, by using publicly available ChIP-seq data (34), we
found that activated FXR can bind directly to the intronic areas
ofGpx2,Gclc,Gsta, andGstm in mouse liver (Table 4), indicat-
ing a universal role of FXR in regulating glutathione metabo-
lism. Mammalian cells possess several protective mechanisms
against damage caused by ROS, with GSH/GSSG homeostasis
playing an important role (52). Gclm, Gpx, and Gsr are the key
enzymes involved in maintaining glutathione metabolism,
which has antioxidant, antiapoptotic, and anti-inflammatory
effects (52). Defective fatty acid oxidation and glutathione
depletion occur not only in the kidney but also in other tissues,
indicating the central role of GSH homeostasis (38, 51). In our
study, FXR activation induced the expression of genes involved
in GSH metabolism and GSH/GSSG homeostasis, thereby
TABLE 4
KEGG analysis
This is a comparison of genes identified in the public ChIP-seq data set (mLiver-GW fromGSE57305) with the PTCs-GW data set (PTCs-GW fromGSE70296) according
to selected categories in DAVID annotation. Genes identified under both “PTCs-GW” and “mLiver-GW” are bolded. GW, GW4064.
Category mLiver-GWa PTCs-GW
Drug metabolism CYP2D9, CYP3A25, CYP2A12, FMO5, GSTM3,
UGT1A7C, ADH4, GSTK1, FMO3, GSTZ1, UGT1A2,
GSTA2, GSTA4, GPX2, CYP3A13, CYP3A11,
GSTT1, GSTT2, CYP2E1, UGT1A1, UGT1A10,
AOX1, CYP2D26, CYP2C38, CYP2C39, MGST1,
GSTA3
Adh7, Cyp2d26, Gsta1, Gsta2, Gsta4,
Gstm3, Gstm1, Ggt1, Gstt2, Gstz1,
Gpx1, Gpx2
Complement and coagulation cascades KNG1, MBL1, KNG2, HC, C3, C4B, CFB, SERPINA1E,
PLG, PROC, SERPINF2, CFH, C2, CFD, FGG, FGA,
FGB, F2, SERPINE1, SERPINC1, CPB2
C3, C4b, Fga, Serpina1e, Serpina1d,
Serpina1c, Serpina1a, Serpinf2
Metabolism of xenobiotics by cytochrome P450 GSTA2, GSTA3, GSTA4, CYP3A25, CYP3A13,
CYP3A11, GSTT1, GSTT2, CYP2E1, UGT1A1,
DHDH, UGT1A10, GSTM3, UGT1A7C, GSTK1,
ADH4, GSTZ1, UGT1A2, CYP2C38, CYP2C39,
MGST1
Adh7, Gsta1, Gsta2, Gsta4, Gstm3,
Gstm1, Gstt2, Gstz1
Pyruvate metabolic process RBP4, GPD1, PCX, G6PC, SDS, PDK4, CAR5A, DLAT,
AGXT, PCK1
Acat2, Acot12, Akr1b7, Me3, Pcx
Fatty acid metabolic process PTGES3, ACOX2, PRKAG3, HACL1, PPARA, PPARD,
SC5D, PRKAG2, STAT5B, ACOT5, ACOT4,
ACOT3, PECR, APOA2, ACSL1, ELOVL5, FASN,
ACOT12, ELOVL6, ACAA1B, ACSL5, SCD1, CPT1B,
ACADM, ALDH5A1, EPHX2, ADIPOR2, LYPLA2,
PHYH, ADIPOQ, CPT1A, BRCA1, QK, PTGDS,
MAPK14, LIPC, AACS, SLC27A2, CROT, SLC27A4,
DEGS1
Acat2, Adh7, Cyp4a12b, Cyp4a12a, Acot3,
Acot4, Acot5, Baat; Acaa1a; Acnat1;
Acot1; Acot12; Acox2; Acsm1; Akr1b7;
Aoah; Apob48r; Apoe, Cubn; Cyp24a1;
Enpp6; Hnf4a; Mogat2; Pcx; Pla1a;
Pla2g12b; Pnpla3; Soat2; Sult1a1,
Prkag2; Slc27a3; Slc37a4
Oxidation reduction CYP2D9, ACOX2, CYP2J5, STEAP3, LDHA, SC5D,
ALDH1L1, PRDX5, PDHB, GPX2, RDH9, PECR,
CYP7A1, CPOX, SRD5A1, DHTKD1, DUS1L,
SARDH, GFOD1, DHCR24, HPD, SQRDL, ACADM,
CYP3A13, ALDH5A1, CYP3A11, CYCS, DECR2,
QDPR, CYP26A1, RDH1, CYP2E1, GRHPR, CDO1,
POR, DHDH, CYP27A1, H6PD, SLC37A2, CYP2D26,
TXNRD2, DEGS1, CYP2U1, XDH, CYP3A25,
NDUFB6,HSD17B2, HSD17B1, HSD17B13, AASS,
MOSC2, EGLN2, Kmo, PAH, ALDH3A2, PIPOX,
CYP2A12, FMO5, ADH4, FMO3, HAAO, FASN,
BDH1, BCKDHA, SCD1, CYP2G1, GPD1, CHDH,
CYP21A1,HGD, PHYH, AKR1B7, CYP17A1,
SLC25A13, LEPRE1, UOX, NDUFV1, CYP4F15,
AOX1, PRODH2, CP, CYP2C38, CYP4A14, ACAD10,
ALKBH2, CYP2C39
Haao, Egln3, Adh7, Fa2h, Gclm, Gpx1,
Gldc, Hgd, Hsd3b2, Hsd3b3, Me3, Miox,
Hsd3b4, Acad10, Acox2; Adhfe1;
Akr1b7; Aldh1a3; Cat; Cmah, Cyp2d26,
Cyp2j11-ps, Cyp24a1, Cyp24a1;
Cyp2c29; Cyp2c44; Cyp2j13; Cyp2j9;
Cyp4a12b, Cyp4a12a; Dcxr; Dhcr24;
Dus1l; Dus2l; Gldc; Gpd1; Gsr;
Hsd11b1; Hsd17b2; Hsd3b3; Kmo;
Maoa; Maob; Nqo1; Prodh2; Qdpr;
Qsox1; Sardh; Sdr42e1; Slc37a4, Sord;
Steap3; Xdh
Glycerophospholipid metabolism CHPT1, GPD1, PEMT, PLA2G6, AGPAT2, AGPAT1,
CRLS1, NAT6, PPAP2C, CHKB, LYPLA2, LCAT,
PHOSPHO1
Agpat2; Etnk1; Pemt; Pi4k2a; Pla2g5
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FIGURE 10. FXR activation enhances glutathione metabolism. A, representative images of glutathione detected in PTCs from different treatment groups.
Violet, glutathione; green, counterstaining for ActinGreen. B, quantification of GSSG andmRNA levels of genes associated with glutathionemetabolism (Gclm,
Gpx1, andGsr) from PTCs undergoing different treatments. Cont, control;GW, GW4064; PA, palmitate acid. C, quantification of GSSG andmRNA levels of genes
associated with glutathione metabolism (Gclm, Gpx1, and Gsr) in mouse kidney from different treatment groups. B and C, n 4/group. Data are expressed as
mean S.E. One-way ANOVA with Bonferroni’s test. *, p 0.05.
FIGURE11.SchemeshowinghowFXRactivationpromotesglutathionemetabolismandreducesFFA-inducedoxidative stress.FFAoxidationgenerates
ROS,which are highly reactivemolecules that oxidize lipids andproteins and cause cellular injury. ROS are scavenged effectively by the thioredoxin reductase/
thioredoxin/peroxiredoxin system. GSH serves as an electron donor to reduce ROS and forms GSSG, mediated by glutathione peroxidase (Gpx). At the same
time, GSH canbe regenerated fromGSSGbyglutathione reductase (Gsr), which keeps a balancedGSHhomeostasis.A, FFAoverload causes increased fatty acid
oxidationand internal generationof excessiveROS.Higher ROS levels place aheavyburdenonmitochondria and theER,where fatty acidoxidation takesplace,
and disturbsmitochondrial function and themitochondrial life cycle. Failure to remove excessive ROS results in defective fatty acid oxidation, oxidative stress,
andER stress.B, in proximal tubular cells, activationof FXRaccelerates glutathionehomeostasis by inducingGSHmetabolic genes, thereby removingexcessive
ROS and reducing oxidative stress. This, in turn, promotes the mitochondrial life cycle, restores mitochondrial and ER function, and prevents cell apoptosis.
FXR and Kidney Injury
JANUARY 29, 2016•VOLUME 291•NUMBER 5 JOURNAL OF BIOLOGICAL CHEMISTRY 2409
 at U
ZH
 H
auptbibliothek / Zentralbibliothek Zuerich on A
ugust 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
counteracting FFA-induced ROS (Fig. 10). Taken together,
these findings indicate that FXR activation induces antioxidant
genes and GSH/GSSG metabolism, both of which block FFA-
induced oxidative stress and promote mitochondrial and ER
function by removing toxic ROS.
Based on the histological changes in tubules and glomeruli
and the higher levels of oxidative and ER stress observed in both
obese mice and humans, therapeutic strategies that target ROS
should delay or reverse kidney disease progression in obese
patients with reduced renal mass (24, 53). Our results indicate
that FXR activation not only ameliorates tubular injury but also
improves renal function by inducing the expression of antioxi-
dant genes. These results suggest FXR as a potential target for
future therapeutic approaches in obese patients with reduced
renal mass secondary to kidney donation and possibly other
forms of kidney impairment.
In conclusion, this study shows that lipid accumulation
occurs in the kidney after exposure to a HFD, leading to
increased ROS levels and associated glomerulosclerosis and
tubulointerstitial fibrosis. These effects are accentuated by uni-
nephrectomy. The bile acid receptor FXR exerts beneficial
effects, because FXR activation reduces glomerular matrix
expansion and interstitial fibrosis, lowers plasma FFA levels,
and decreases lipid accumulation in the remaining kidney of
UNX mice. Moreover, FXR activation prevents FFA-induced
oxidative stress and ER stress by promoting antioxidant path-
ways and regulating glutathione metabolism, providing a likely
explanation for the beneficial effects observed.
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